IIL

Innate Immunotherapeutics shifts market focus via proposed biotech acquisition

Innate Immunotherapeutics (ASX: IIL) is proposing to absorb Amplia Therapeutics, a privately-owned Melbourne-based biopharmaceutical company, via an all-share deal to acquire the company including its ongoing highly-prized anti-cancer therapies. The move effectively repositions the company’s operations and current market standing within immune-oncology, as part of what Innate CEO Simon Wilkinson says is a “logical move” […]